About this trial

This multicenter, prospective, single-arm study aims to evaluate the efficacy of inhaled nitric oxide (iNO) in neonates with congenital diaphragmatic hernia (CDH) and early pulmonary hypertension. Short-term treatment response will be assessed by the changes in oxygenation index and other parameters including echocardiographic parameters at predefined intervals.

Eligibility criteria

Qualifiers

Bochdalek type congenital diaphragmatic hernia

Gestational age at 34 weeks or more and within 14 days after birth

Hypoxic respiratory failure and pulmonary hypertension

Disqualifiers

Combined congenital heart disease requiring neonatal intervention or surgery

Previous treatment of pulmonary vasodilators including inhaled nitric oxide

on ECMO treatment

Trial design

Treatments tested in this trial

  • Inhaled Nitric Oxide

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

4
Asan Medical Center05505, SeoulSeoul, South Korea
Chonnam National University Hospital44935, Gwangju South Korea
Seoul National University Children's Hospital03080, Seoul South Korea
Severance Hospital03722, Seoul South Korea

Sponsors and collaborators

Asan Medical Center

Lead sponsor

Seoul National University Hospital

Collaborator

Severance Hospital

Collaborator

Chungnam National University Hospital

Collaborator